
SWTX Stock Forecast & Price Target
SWTX Analyst Ratings
Bulls say
SpringWorks Therapeutics Inc. is strategically positioned to capitalize on its recent product approvals, OGSIVEO and GOMEKLI, which are expected to drive significant market interest and create potential acquisition opportunities within the biopharmaceutical sector. With approximately $461.9 million in cash and cash equivalents as of the end of 2024, the company is well-funded to support its operations until projected profitability in 2026. The competitive clinical profiles of its products, particularly GOMEKLI's broader market access compared to existing treatments, enhance its outlook for outperforming initial estimates, underscoring SpringWorks's attractiveness as a promising oncology enterprise.
Bears say
SpringWorks Therapeutics is projected to incur a full-year net loss of $2.65 million in 2025, indicating potential financial strain. The company faces substantial risks related to the commercialization and market expansion of its key products, nirogacestat and mirdametinib, as well as the possibility of clinical setbacks with other candidates like brimarafenib. Additionally, the threat of long-term dilution poses a further risk to investors, particularly in light of the dependence on achieving regulatory and clinical success for its developmental programs.
This aggregate rating is based on analysts' research of SpringWorks Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SWTX Analyst Forecast & Price Prediction
Start investing in SWTX
Order type
Buy in
Order amount
Est. shares
0 shares